News

Filter

Current filters:

None

64 to 73 of 96597 results

Eurofins Genomics extends genomic business into Austria and Czech Republic

Eurofins Genomics extends genomic business into Austria and Czech Republic

21-10-2014

Eurofins Genomics, the genomics division of the Eurofins Scientific Group, and international market leader…

AustriaBiotechnologyEurofins GenomicsGeneticsMarkets & Marketing

Ashland Specialty Ingredients opens new pharma center in Wilmington, Delaware

Ashland Specialty Ingredients opens new pharma center in Wilmington, Delaware

21-10-2014

Ashland Specialty Ingredients, the commercial unit of Ashland Inc, has opened a new pharma center in…

AshlandAshland IncPharmaceuticalProductionUSA

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

FDA panel unanimously backs Novartis’ secukinumab for moderate-to-severe plaque psoriasis

21-10-2014

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration…

DermatologicalsNovartisPharmaceuticalRegulationsecukinumabUSA

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

20-10-2014

The US Food and Drug Administration has granted Fast Track designation for TAS-102 (trifluridine and…

OncologyOtsukaPharmaceuticalRegulationTaiho OncologyTAS-102USA

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

20-10-2014

Japanese drug major Eisai has had a supplemental New Drug Application for its in-house-discovered AMPA…

CNS DiseasesEisaiFycompaJapanPharmaceuticalRegulation

NewLink Genetics out-licenses NLG919 to Genentech

NewLink Genetics out-licenses NLG919 to Genentech

20-10-2014

US biotech firm NewLink Genetics saw its share price rocket 21.2% in morning trading today, after it…

BiotechnologyGenentechGlobalLicensingNewLink GeneticsNLG919OncologyRoche

AnaptysBio appoints Marco Londei as chief development officer

AnaptysBio appoints Marco Londei as chief development officer

20-10-2014

Therapeutic antibody specialist AnaptysBio has appointed Marco Londei as chief development officer, leading…

AnaptysBioBoardroomBristol-Myers SquibbMarco LondeiUSA

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Valeant third-qtr profits beat expectations

20-10-2014

Canadian drugmaker Valeant Pharmaceuticals International has posted third-quarter 2014 financial results…

AllerganFinancialGenericsMergers & AcquisitionsValeant Pharmaceuticals International

64 to 73 of 96597 results

Back to top